GlaxoSmithKline PLC Ownership
| GSK Stock | USD 36.17 0.38 1.04% |
Shares in Circulation | First Issued 2009-03-31 | Previous Quarter 2.1 B | Current Value 2.1 B | Avarage Shares Outstanding 2 B | Quarterly Volatility 51.1 M |
GlaxoSmithKline |
GlaxoSmithKline Stock Ownership Analysis
About 17.0% of the company shares are owned by institutional investors. The book value of GlaxoSmithKline PLC was currently reported as 3.35. The company has Price/Earnings To Growth (PEG) ratio of 0.81. GlaxoSmithKline PLC ADR last dividend was issued on the 21st of February 2025. The entity had 1226:1000 split on the 22nd of July 2022. GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. Gsk Plc is traded on New York Stock Exchange in the United States. To learn more about GlaxoSmithKline PLC ADR call Emma Walmsley at 44 20 8047 5000 or check out https://www.gsk.com.Besides selling stocks to institutional investors, GlaxoSmithKline PLC also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different GlaxoSmithKline PLC's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align GlaxoSmithKline PLC's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
GlaxoSmithKline PLC Quarterly Liabilities And Stockholders Equity |
|
Less than 1% of GlaxoSmithKline PLC ADR are currently held by insiders. Unlike GlaxoSmithKline PLC's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against GlaxoSmithKline PLC's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of GlaxoSmithKline PLC's insider trades
GlaxoSmithKline Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as GlaxoSmithKline PLC is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading GlaxoSmithKline PLC ADR backward and forwards among themselves. GlaxoSmithKline PLC's institutional investor refers to the entity that pools money to purchase GlaxoSmithKline PLC's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Eversept Partners, Llc | 2024-09-30 | 4.1 M | Equity Investment Corp | 2024-12-31 | 4 M | Arrowstreet Capital Limited Partnership | 2024-09-30 | 3.9 M | Grantham, Mayo, Van Otterloo & Co., Llc | 2024-09-30 | 3.7 M | Hotchkis & Wiley Capital Management Llc | 2024-09-30 | 3.5 M | Camber Capital Management Llc | 2024-09-30 | 3 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 2.6 M | Hsbc Holdings Plc | 2024-09-30 | 2.6 M | Renaissance Technologies Corp | 2024-09-30 | 2.3 M | Dodge & Cox | 2024-09-30 | 68.1 M | Fmr Inc | 2024-09-30 | 29 M |
GlaxoSmithKline PLC's latest congressional trading
Congressional trading in companies like GlaxoSmithKline PLC ADR, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in GlaxoSmithKline PLC by those in governmental positions are based on the same information available to the general public.
| 2024-11-28 | Representative Marjorie Taylor Greene | Acquired Under $15K | Verify | ||
| 2023-11-16 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2023-11-15 | Senator Tommy Tuberville | Acquired Under $15K | Verify |
GlaxoSmithKline PLC Outstanding Bonds
GlaxoSmithKline PLC issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. GlaxoSmithKline PLC ADR uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most GlaxoSmithKline bonds can be classified according to their maturity, which is the date when GlaxoSmithKline PLC ADR has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US377320AA45 Corp BondUS377320AA45 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| GLAXOSMITHKLINE CAPITAL PLC Corp BondUS377373AH85 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| GLAXOSMITHKLINE CAP INC Corp BondUS377372AM97 | View | |
| GLAXOSMITHKLINE CAP INC Corp BondUS377372AN70 | View |
GlaxoSmithKline PLC Corporate Filings
6K | 13th of February 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.167 | Dividend Share 0.61 | Earnings Share 1.55 | Revenue Per Share | Quarterly Revenue Growth 0.008 |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.